EMBC
Embecta Corp

172
Loading...
Loading...
News
all
press releases
Best Income Stocks to Buy for September 15th
CZNC, EMBC and FFBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 15, 2025.
Zacks·19d ago
News Placeholder
More News
News Placeholder
New Strong Buy Stocks for September 15th
RNGR, LRN, BWA, KT and EMBC have been added to the Zacks Rank #1 (Strong Buy) List on September 15, 2025.
Zacks·19d ago
News Placeholder
Best Value Stocks to Buy for September 9th
JXN, EMBC and KT made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 9, 2025.
Zacks·25d ago
News Placeholder
Embecta Corp. (EMBC) Crossed Above the 200-Day Moving Average: What That Means for Investors
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?
Zacks·1mo ago
News Placeholder
Wall Street Analysts Predict a 25.69% Upside in Embecta Corp. (EMBC): Here's What You Should Know
The consensus price target hints at a 25.7% upside potential for Embecta Corp. (EMBC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·2mo ago
News Placeholder
Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates
chainwire·5mo ago
News Placeholder
Embecta Corp. Tops Q3 Earnings and Revenue Estimates
Embecta Corp. (NASDAQ: EMBC) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.69 per share a year ago...
Benzinga·1y ago
News Placeholder
Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company
Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company PR Newswire NEW YORK, July 29, 2024...
PR Newswire·1y ago
News Placeholder
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company's U.S. business has struggled with the rise of GLP-1 drugs and...
Benzinga·1y ago
News Placeholder
Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors
Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors PR Newswire WARSAW, Ind., June 20, 2024...
PR Newswire·1y ago

Latest EMBC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.